Pharma trademarks in Brazil: an exception to the rule
A massive investment in time and money is required through the phases of research, development and launch of a new product in the market. Even when the product is ready to be produced on a large scale, pharmaceutical companies still depend on marketing approval from the Food and Drug Agency (in Brazil, this is called Anvisa).
